# A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

> **NCT07233655** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- Moderate to Severe Active Rheumatoid Arthritis

## Interventions

- **DRUG:** SHR-3045 Injection
- **DRUG:** SHR-3045 Injection Placebo

## Key facts

- **NCT ID:** NCT07233655
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2026-04-21
- **Final completion:** 2026-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233655, "A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07233655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*